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Background: Large-scale RNAi screening has become an important technology for identifying genes involved in
biological processes of interest. However, the quality of large-scale RNAi screening is often deteriorated by off-targets
effects. In order to find statistically significant effector genes for pathogen entry, we systematically analyzed entry
pathways in human host cells for eight pathogens using image-based kinome-wide siRNA screens with siRNAs from three
vendors. We propose a Parallel Mixed Model (PMM) approach that simultaneously analyzes several non-identical screens
performed with the same RNAi libraries.
Results: We show that PMM gains statistical power for hit detection due to parallel screening. PMM allows incorporating
siRNA weights that can be assigned according to available information on RNAi quality. Moreover, PMM is able to estimate
a sharedness score that can be used to focus follow-up efforts on generic or specific gene regulators. By fitting a PMM
model to our data, we found several novel hit genes for most of the pathogens studied.
Conclusions: Our results show parallel RNAi screening can improve the results of individual screens. This is currently
particularly interesting when large-scale parallel datasets are becoming more and more publicly available. Our
comprehensive siRNA dataset provides a public, freely available resource for further statistical and biological analyses in
the high-content, high-throughput siRNA screening field.
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Large-scale RNAi screening is a widely used technology to
knock-down expressions of genes and study their protein
function in a biological process of interest [1-5]. In several
published studies in the field of infection biology, cells per-
turbed with siRNAs were exposed to pathogens and differ-
ences in phenotypic outcomes were measured in order to
identify the genes involved in successful infection or to* Correspondence: christoph.dehio@unibas.ch
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unless otherwise stated.develop functional models of host signaling and trafficking
pathways [6-9].
RNAi libraries are mostly sold in formats containing
enough material for numerous large-scale screens. There-
fore, several large-scale siRNA screens are typically
performed using the same libraries within a unit such as a
university or company in order to optimize material costs
and to simplify plate handling. However, parallel screens
are typically performed and analyzed separately without
common protocols or analysis pipelines. Therefore,
comparing results between the screens is challenging.
Co-operative efforts, such as assays using common key
parameters for imaging and data analyses, could enable tohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mation for each individual screen. In the field of RNAi
screening, there has been progress in relation to the
standardization of data publication formats, in particular
in the context of the “Minimum Information About an
RNAi Experiment” (MIARE, http://miare.sourceforge.net)
and GenomeRNAi [10] efforts. However, the provided
metadata information and data analysis approaches are
often diverse so that data comparison between the screens
from different laboratories is very difficult.
Poor reproducibility rates of large-scale RNAi screens
are a common concern. They are mostly caused by strong
off-target effects from particular siRNAs [11-16]. Strat-
egies have been proposed to alleviate the confounding ef-
fects of RNAi screens, including experimental [17,18] and
statistical approaches [9,19-22]. In this study, we aim to
use the parallel screening structure in order to gain statis-
tical power for hit selection in large-scale RNAi screens.
We generated high-content siRNA datasets that are
uniquely comprehensive in terms of the siRNA libraries
and various pathogens used. We employed highly unified
protocols for parallel screens and common data analysis
pipelines to allow a direct comparison between the read-
outs of different pathogen screens. In addition to obtain a
list of hits for individual pathogens, our aim was to
discover shared mechanisms between pathogens. To this
purpose, we propose a new statistical method – the Paral-
lel Mixed Model (PMM). Our approach simultaneously
takes into account the knock-down effects of several
non-identical screens performed in parallel with the same
RNAi libraries. Additionally, the PMM provides a local
False Discovery Rate (FDR) for every gene, resulting in a
probability estimate that a gene is a false positive. We will
show that the model improves statistical power thanks to
parallel screening and that it yields stable hits, novel to the
studied pathogens, without compromising the detection of
unique hits for any given single screen.
Results and discussion
High-content siRNA screening
Our InfectX consortium, consisting of eleven research
groups, generated kinome-wide siRNA screens for five
bacterial pathogens (Bartonella henselae, Brucella abor-
tus, Listeria monocytogenes, Salmonella typhimurium,
and Shigella flexneri) and three viruses (Adenovirus,
Rhinovirus, and Vaccinia virus) and systematically
analyzed the biological pathways leading to successful
infection in human host cells (Figure 1). This choice of
bacterial and viral pathogens covered a wide variety
of mechanism to invade host cells. B. henselae, for
example, invades host cells by invasome structures [23],
the pathogens S. typhimurium and S. flexneri use the
trigger mechanism, while L. monocytogenes uses the zip-
per mechanism [24]. Adenovirus and Rhinovirus enterby a dynamin and clathrin dependent pathway [25] and
Vaccinia virus by macropinocytosis [26].
We conducted the screens in a highly parallel manner
under one common protocol for all eight pathogens. We
carried out all screens in the same HeLa ATCC-CCL-2
cell line and with the same reagent batches of shared pro-
viders. The set of 826 targeted genes comprised almost
the whole kinome, plus selected kinome-associated genes,
and we targeted each gene by a total of eleven independ-
ent siRNAs coming from three manufactures: Ambion
(Silencer Select) with 3 siRNAs per gene, Qiagen (Human
Kinase siRNA Set V4.1) with 4 siRNAs per gene and
Dharmacon (Human ON-TARGETpIus) with 4 siRNAs
per gene. Additionally, we performed screens where we
targeted each kinase with a pool of the four Dharmacon
siRNAs (Human ON-TARGETpIus SMARTpooI). How-
ever, not all of the 826 genes have a full set of 11 siRNAs
and 1 siRNA pool available. Depending on the pathogen
and library, we independently repeated the screens one to
six times as replicates (see Additional file 1: Table S1). To
obtain an optimal dynamic range of infectivity, we chose
the pathogen dose and entry time to be pathogen specific
(see Additional file 1: Table S2). We fixed and stained the
cells using DAPI or Hoechst to detect nuclei, fluorescent
labeled phalloidin to detect actin filaments and the cell
body, and a pathogen specific marker to detect infected
cells. In a final step, we imaged the screens using micro-
scopes of the same brand. Thus, we only permitted devia-
tions from the common protocols when the infection
assay required it.
We separately optimized image analysis for each patho-
gen and established for each pathogen a list of image fea-
tures that described the phenotypes of infected cells. For
example, for S. flexneri, we chose as one feature the RFP
intensity of the extracted bacteria objects and for L. mono-
cytogenes the mean Cy3 intensity of the cell (see Figure 1A
and Additional file 1). In the next step, we classified the
cells in each well as infected or uninfected with a Decision
Tree Infection Scoring (DTIS) algorithm (see Additional
file 1) and obtained a rate of infection per well (infection
index) (Figures 1B–C). Besides assay-specific readouts the
image analysis also provided several assay-independent
readouts (e.g. cell number). We alleviated possible batch
effects, dependencies to the population context, and fur-
ther experimental confounders by data normalization (see
Additional file 1) [27-32]. We performed all analyses pre-
sented in this paper with the normalized infection index
readout, unless otherwise stated.
Data reproducibility
Our data confirmed the reported [20] low reproducibil-
ity rates of siRNA data originating from different siRNAs
targeting the same genes. The normalized infection indi-
ces of two different siRNA sets targeting the same genes
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Figure 1 Overview of InfectX high-content datasets, image analysis, and Parallel Mixed Model (PMM). (A) The figure shows example
images of the different pathogens after siRNA transfection and the infection phase. The arrows indicate typical infectious phenotypes for each
pathogen. The list shows an example of three single cell features that we extracted to identify infected cells for L. monocytogenes. The scale bar
has a length of 50 μm. (B) For each selected feature, we defined the optimal threshold that separated best between uninfected and infected
cells via histograms. We used the thresholds in the Decision Tree Infection Scoring (DTIS) algorithm to classify between infected (green) and
non-infected cells (red). We optimized this procedure for each pathogen separately. (C) For each well in a 384-well assay plate, we calculated the
infection index by dividing the number of infected cells (green) by the total number of cells (green and red). (D) The figure shows a schematic
representation of the input data for the statistical analysis. Each point represents the average infection index over all its replicate wells (wells with
the same siRNA set targeting the same gene and pathogen). (E) The Parallel Mixed Model (PMM) algorithm fits via a normal distribution for an
overall effect ag to all data of gene g. The second plot shows the correction of the overall effect ag within every pathogen by an estimate bpg in
order to obtain to an pathogen and gene specific effect cpg. The different sizes of the data points refer to weights ws which can be incorporated
in the PMM to depict the quality of the siRNA. (F) The figure shows a schematic representation of the final output of PMM. The model estimates
gene effects cpg for each gene and pathogen and provides corresponding local False Discovery Rates qpg.
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and 0.2 depending on the screens (Figure 2B). Adding
independent siRNAs to the screen yielded an increase inthe correlation coefficients, but the correlation still
stayed at an unsatisfactory level, even with six separate
siRNAs targeting each gene (R was between 0.1–0.4 in
Figure 2 Using more siRNAs adds power and yields reproducible results. (A) The three boxplots show Pearson correlation coefficients R
between screens performed using the same siRNA set. The numbers 1 to 3 correspond to the total number of replicate screens that we averaged
and compared to another distinct set of replicate screens, averaged over the same number. We resampled the replicate screens up to 500 times.
The scatter plot shows an example for the correlation of infection indices from the duplicate of Adenovirus Dharmacon pooled screen.
(B) The set of six boxplots shows the Pearson correlation coefficients of the averaged readouts from 1 to 6 siRNA sets. The scatter plots depict
the correlation of infection indices for Adenovirus, the first between two different single siRNAs and the second between each an average over
six siRNAs.
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In contrast, replicate screens (screens performed using
the same protocols and siRNA set, but performed at a
different time) were reproducible (R was between 0.5–
0.9) (Figure 2A). For practical reasons, assuming a simi-
lar assay quality as ours, performing screens in dupli-
cates seems sufficient since having more replicates does
not improve the data to a great extent (Figure 2A). On
the other hand, performing screens at least in duplicates
is necessary for quality control and performing only
single screens is therefore not recommendable. The
cell number readouts (see Additional file 1: Figure S4)
showed qualitatively similar results for data reproducibil-
ity. In summary, the main error source in our siRNA
screening was the bias caused by varying specificity of
siRNAs and not by technical variability of the screens.
Parallel Mixed Model (PMM)
Assuming that the sources of variability between different
siRNAs targeting the same gene are statistically independ-
ent, we can benefit from the fact that the true signal is
enhanced by using more siRNAs targeting the individual
genes [17] (Figure 2B). In order to increase the statistical
power of individual siRNA screens, we performed screens
with 11 siRNAs (and one pool of siRNAs) targeting each
gene. Moreover, when using the parallel structure in the
data and combining data points from all pathogen screens
together, we reached 8×12 = 96 data points for every gene(averaging over the replicate screens). We propose the
Parallel Mixed Model (PMM) as a suitable approach to
model the distribution of the siRNA readouts using all
data together, including all available siRNAs and pathogen
screens.
PMM is composed of a linear mixed model and an
assessment of the local False Discovery Rate (FDR)
(Figure 1E–F). The linear mixed model is an extension of
the ordinary linear model by random effects [33]. In par-
ticular, random effects are not determined by fixed coeffi-
cients, but by Gaussian distributions. Therefore, we can
incorporate the variation among the siRNAs in form of
random effects and estimate all effects for different patho-
gens simultaneously. To be more precise, the linear mixed
model consists of a fixed effect μp for pathogen p and two
random effects ag for gene g and bpg as a correction term
for gene g within pathogen p:
ypgs ¼ μp þ ag þ bpg þ εpgs;
where ypgs denotes the readout (for example the normal-
ized infection index of a well) of pathogen p and gene g
knocked-down with siRNA s and εpgs denotes the unob-
served error term. We fitted the linear mixed model by
using the “lmer” function from the “lme4” R-package
[34]. The sum of two random effects ag and bpg describes
the total effect of the siRNAs within pathogen p. We
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p as
cpg ¼ ag þ bpg :
A positive estimated cpg effect means that the infection
level was enhanced if the corresponding gene g is
knocked down. A negative effect means that the infec-
tion level was reduced. To distinguish hit genes, PMM
provides as second step an estimate qpg of the local False
Discovery Rate (FDR). We computed the local False
Discovery Rate using the approach presented in [59] and
the “locfdr” function in the R-package of the same name
[35]. We assigned the local False Discovery Rate to every
gene and interpreted it as the probability describing how
likely the corresponding gene is a false discovery
(see Methods for more details). The PMM method is
published as “PMM” R-package on the InfectX data-
access page.
As a first verification for the increase in power by
simultaneously using the parallel screening structure, we
resampled datasets, each consisting of a fixed number of
siRNAs and pathogens, and fitted the PMM, respectively
the Moderated T-Test (MTT) [36] for the case of one
pathogen (see Methods for details). We evaluated the
mean and variation (i.e. stability) of the ranks in the
ordered lists of genes based on their estimated cpg valuesMET (Unique hit)
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Figure 3 Parallel screens add power to find more shared hits. (A) We
rank of MET for L. monocytogenes in the ordered list of hit genes. We used
resampling rounds with replacement. The color corresponds to the variatio
strong hit among the studied pathogens. The star indicates the boxplots th
(B) The figure shows the same experiment as in (A), but now with MTOR f
hit for several pathogens. (C) The figure shows the same experiment as inover 1000 resampling runs for MET (a known effector
gene for L. monocytogenes [37]), MTOR (a role of MTOR
in the infection pathways of several pathogens has already
been established [6,15,38]) and a non-hit ALK as control
(Figure 3). The results showed, in particular in the case of
MTOR, that the rank and its stability improved by simul-
taneously using more siRNAs and pathogens. In the case
of MET the use of parallel screens did not cause an
increase in statistical power, since MET was a hit for L.
monocytogenes only. However, for MET there was no re-
duction of statistical power either. These examples already
indicated that the parallel screening structure and PMM
can be used to more reliably discover expected effector
genes even in the case where only a fraction of effector
genes is shared between the screens.
Analysis of siRNA libraries
PMM allows the assignment of weights to each siRNA
(see Methods). With weighting, we can assign more
power to siRNAs that are estimated to have little
off-target effects and strong knock-down efficiencies.
Within this study, we weighted siRNAs according to the
reproducibility in terms of correlation of their corre-
sponding library to other libraries (Figure 4A). There
are several potential other ways how weights could be
determined. However, we did not follow them further
within the context of this paper.ALK (Control non-hit) 
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PMM (and MTT for the case of one pathogen) over 1000 random
n of the observed ranks. The boxplot shows that MET is a unique
at are significantly different from 0 (one sample t-test p < 0.05).
or Vaccianiavirus. The boxplot shows that MTOR is a shared significant
(A) but with non-hit ALK for B. abortus for control.
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Figure 4 Statistics on used siRNA libraries and hits. (A) We weighted siRNAs based on their library quality. Each vertical compartment in the
plot corresponds to a training set of siRNAs. We averaged data in the training set from the siRNAs of the specific manufacturers. Each boxplot
corresponds to a test set of single siRNAs from different manufacturers (except “Dharm. siRNA mean” which is the average of 4 Dharmacon
unpooled siRNAs). Y-axis refers to Pearson correlation coefficients R between the training and test sets. A star corresponds to significant differences in the
correlation coefficients (Mann–Whitney-U-test p < 0.05) between pairs of manufacturers. We used all screens, infection index, and cell number well readouts
in the analysis. We used the results of this analysis to assign siRNA weights to siRNAs from different library manufacturers as shown below the plot. (B) The
histogram shows obtained FDR q-values from all screens using the infection index readouts. The red line shows the FDR-threshold of 0.4. (C) The bar
shows number of up and down hits for different pathogens. (D) The bar plot shows the number of hit genes that were shared between pathogens.
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http://www.biomedcentral.com/1471-2164/15/1162We cross-validated different libraries to each other by
fixing one library manufacturer (training set) at a time
(Figure 4A). We averaged phenotypic readouts from siR-
NAs targeting the same gene in the training set in order
to obtain reference gene readouts. In this analysis we
used both infection index and cell number readouts. We
then compared single siRNA readouts of the remaining
two library manufactures (test set) to the reference genereadouts. The Pearson correlation coefficients of the test
sets enable to quantify which of the two test manufac-
turers produces more reproducible results. By repeating
the procedure for all manufacturers as the training set
we could order the manufacturers in terms of their re-
producibility performance. Our results based on pheno-
typic readouts showed that the pooled Dharmacon
library performed the best. The pooled library was
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http://www.biomedcentral.com/1471-2164/15/1162followed by the unpooled libraries of Ambion, Dharmacon,
and Qiagen in this order. However, there were no sta-
tistically significant differences (Wilcoxon rank-sum test
p < 0.05) between Dharmacon pooled and Ambion single,
and Dharmacon single and Qiagen single siRNA data
reproducibility. In addition, the data showed that the aver-
aged single siRNAs of Dharmacon performed at most asRhinovir
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Figure 5 Summary of screening hits for all pathogens. (A) The heat m
pathogen. We ordered the genes by their averaged c-values over all patho
outlines indicate significant hits (FDR < 0.4) and the green outlines high-lig
column shows the sharedness scores for each gene. (B) The network show
neighbors that had connections between kinases in STRING database (vers
with edge threshold 850. We removed genes that were not connected to
chart, in which each piece corresponds to a pathogen.good as the single pooled siRNA consisting of the same siR-
NAs. This indicated that for most screening purposes, it is
more practical to use the pooled library instead of several
unpooled libraries. This result of better performance of
pooled libraries compared to averaged single siRNA librar-
ies is in contradiction with what has been reported in [19].
However, good quality single siRNA libraries (such asAdenovirus
B. henselae
B. abortus
L. monocytogenesus
rus
ap shows all genes which were significant (FDR < 0.4) at least for one
gens. The colors correspond to the estimated c-values. The black
ht the strongest down and up hits for each pathogen. The rightmost
s the hit genes (FDR < 0.4 for at least one pathogen) and their direct
ion 9.0). The edges are functional interactions in the STRING database
any other gene from the network. Each node consists of a colored pie
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http://www.biomedcentral.com/1471-2164/15/1162Ambion Silencer Select) performed nearly as well as pooled
libraries of less good single siRNAs (in our case Dharmacon
SMARTpool). Following the results of the library analysis,
we assigned a higher weight to Dharmacon Pooled and
Ambion libraries (weight 2) than to the unpooled libraries
Dharmacon and Qiagen (weight 1). PMM benefitted from
the assigned library weights. The residual standard error of
the linear mixed model reduced from 0.87 to 0.83.
Sharedness of detected significant genes
By fitting PMM to our data, we found a left tailed local
False Discovery Rate distribution, ending with a set of 50
different genes that reached the threshold of 0.4 (Figure 4B,
Figure 5A). We selected threshold 0.4 as a reasonable hit
threshold for this study since the difference was small
compared to the set of hits with the commonly used
threshold 0.2 and 40% false-positive rate was still ac-
ceptable in biological follow-up studies for us. The num-
ber of up and down hits varied between the pathogens
(Figure 4C). Using FDR threshold 0.4, 80% of hits were
unique and 20% of hits were shared between two or more
studied pathogens (Figure 4D). This provided a rough esti-
mate that about 20% of genes gained statistical power
from the parallel analysis using the PMM with our data.
To quantify the hits according to their level of being
shared between screens independently from the FDR-
threshold, we developed the following “sharedness score”
sg:
sg ¼ 12 1−Meanp qpg
  
þ
X
p
qpg < 1
 
P
0
@
1
A:
Here P is the total number of pathogens (8 in our case).
The sharedness score is a combination of two quantities.
The first part defines the shift away from 1 and the second
part describes how many pathogens support this shift
(proportion of qpg < 1). The score returns a value between
0 and 1 for each gene. Score 0 indicates that a gene is not
shared among the pathogens and score 1 indicates that
the gene is significant among all pathogens (Figure 5A).
Since the sharedness score takes only the strength of a
gene and not the directionality into account, a gene can be
also highly shared if it inhibits in one pathogen and
enhances the infection by another pathogen. Therefore, a
gene shared between pathogens should be interpreted as
being involved in the entry of these pathogens.
Result comparison to existing hit ranking methods
In order to validate the PMM approach and its results
we compared it to other existing hit ranking methods
and performed different kind of statistical tests. As refer-
ence methods we selected the Moderated T-Test (MTT)
[36] and Redundant SiRNA Activity (RSA) [39] whichare commonly used in high-throughput RNAi screening.
We could not apply other widely used hit ranking
methods, such as Strictly Standardized Mean Difference
(SSMD) [40] or percent inhibition [29] since many of
our pathogen screens did not have effective and reliable
positive and negative control wells.
As a first test, we analyzed the stability of the obtained
gene rankings with respect to the estimated cpg values
[30,41]. We resampled with replacement 1000 datasets
(12 siRNAs randomly selected with replacement for each
gene) and calculated the number of genes that appear
with high probability (prob > 0.9 and prob > 0.7) in the
top of the ordered lists of genes based on their estimated
cpg values (see Methods for details). This measure of sta-
bility showed similar results for PMM and the reference
methods MTT and RSA (Figure 6A).
To mimic primary and validation screening setup and to
study hit reproducibilities of the gene ranking methods we
performed a leave-one-out cross-validation experiment.
We used the siRNAs of unpooled libraries (11 in total)
and left one siRNA set at a time away. We ran PMM,
MTT, and RSA on the data sets consisting of 10 individual
siRNAs and compared the resulting gene ranking to the
ranked gene list of the remaining siRNA set. The averaged
hit overlaps over all pathogens as a function of hit thresh-
old k are illustrated in Figure 6B. PMM performed the best
indicating that the hits found by PMM are more reprodu-
cible by an independent siRNA screen than the hits found
by the other methods.
In order to further estimate the hit-calling performance
for different methods we performed data simulation with
a-priori known hit structure. Data simulation was required
since reliable ground truth hits are not generally available
for the real biological systems. We simulated data by gen-
erating 1000 Gaussian distributed screens for each patho-
gen with four siRNAs. We selected four siRNAs since it
makes up a realistic screening approach. We incorporated
hits in each simulated screen by randomly selecting 10%
of the genes and shifting them away from zero. We distin-
guished between three types of simulated data. In the first
case the hits were different for each pathogen (unique hits
only) and in the second case all hits were shared between
the pathogens. The third case is probably the most realis-
tic scenario containing both unique and shared hits to a
varying degree (see Methods). We then applied PMM,
MTT, and RSA to the simulated data and evaluated them
by Receiver Operating Characteristic (ROC) -curves (with
false positive versus true positive rates plotted for each
FDR- threshold; Figure 6C–E). The results showed that
PMM performed the best especially in the case of shared
hits. For the case of unique hits PMM and MTT exhibited
about the same performance while RSA performed the
worst. As expected, with a higher shift of the hit genes the
ROC curves got better for all methods.
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Figure 6 Performance statistics of hit ranking methods. (A) The figure shows stability curves using the three different methods (PMM, MTT
and RSA). The y-axis denotes the number of genes that were found with probability higher than 0.7 (dashed lines) and 0.9 (solid lines) in the top
k (x-axis) of the list of ranked genes. The curves show the average over all eight pathogens. (B) The figure shows hit overlaps of cross-validated
siRNA sets between the set of 10 unpooled siRNA libraries and the remaining siRNA library using the three tested gene ranking methods as a
function of hit threshold k. The curves show the average over all eight pathogens. (C) The figure shows ROC-curves for PMM, MTT and RSA
applied on simulated data containing only hits that were shared between all pathogens. The dashed and solid lines indicate whether the shifts
were generated by a low or high shift away from zero. The PMM method outperformed the reference hit detection method. (D) The figure
shows ROC-curves for PMM, MTT and RSA applied on simulated data containing only unique hits for all pathogens. PMM and Moderated T-Test
performed equally well. (E) The figure shows ROC-curves for simulated data with a mixed hit structure of both unique and shared hits. The PMM
method outperformed the reference hit detection method.
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ranking of genes in individual screens using PMM. We
performed a test where we selected a pathogen and cre-
ated two datasets. The first dataset was the full data with-
out any changes and the second dataset had the original
data for the selected pathogen and randomized data for
the 7 other pathogens. We then compared the gene rank-
ings obtained by PMM performed using both datasets for
the selected pathogen. The results for L. monocytogenes
are illustrated in Figure 7A (see Additional file 1: Figure S6
for all the other pathogens). The correlation graph shows
that the addition of parallel screens had only a mild effect
on the overall gene ranking. However, when considering
the number of significant genes (FDR < 0.4), PMM mainly
added genes to the list of significant genes (7 novelsignificant genes for L. monocytogenes) and only few genes
(1 for L. monocytogenes) were dropped off the list. In
general, we concluded that using parallelism added novel
significant genes while losing almost none. Moreover, the
few lost hit genes had high FDR values, just slightly below
the selected threshold FDR < 0.4.
In the next step we analyzed the differences between the
resulting gene rankings of the tested methods. Differences
in gene rankings between PMM and other hit ranking
methods were not very strong (see Figure 7B for MTTcom-
pared to PMM for L. monocytogenes and Additional file 1:
Figure S7 for all other cases). Genes that had a high shared-
ness score and had an effect on the screen of interest (in
particular MTOR and TGFBR1/2 for L. monocytogenes)
gained statistical power from the simultaneous analysis and
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Figure 7 Summary of differences of PMM top hits compared to other hit scoring methods. (A) Y-axis shows the PMM gene ranking for L.
monocytogenes. X-axis is the same, but we randomized the other 7 parallel assays. The colors correspond to hit genes (FDR < 0.4) in different
cases. Parallelism yielded only a slight effect on the ranking, but added genes to the list of significant hit genes. (B) The scatter plot shows PMM
hit ranking (y-axis) compared to the MTT hit ranking (x-axis) for L. monocytogenes. The dot size corresponds to the sharedness score of each gene.
Some genes with high sharedness scores gained statistical power.
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observed that PMM detected several genes with low shared-
ness scores, indicating that unique hits were not neglected.
In order to evaluate the biological relevance of ob-
served hits, we calculated pathway enrichment scores
separately for each pathogen by the Gene Set Enrich-
ment Analysis (GSEA) algorithm [42] using as input the
results from the three hit ranking algorithms PMM,
MTT, and RSA (see Additional file 1). We selected all
pathways that were significant (GSEA pathway enrich-
ment FDR score < 0.2) for at least one pathogen andmethod pair. We used the ranking of infection indices as
the input for GSEA and focused on hits that reduce
infection levels. By assuming that most pathways in the
used database are biologically valid, we would expect
that better hit detection methods give a higher number
of enriched pathways than less powerful hit detection
methods. However, we only screened kinases and the
applicable pathways are limited to those that are highly
enriched in phosphorylation events and it may be that
some pathogens do not show strong enrichments within
this set of pathways. Moreover, differences in pathway
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cause they treated missing values differently. Therefore,
the enrichment results should be evaluated with caution.
Additional file 1: Figure S9 illustrates the observed sig-
nificant pathways. The number of enriched (GSEA FDR
< 0.2) pathways for each method was an indication that
PMM detected biologically more relevant hit genes than
the other methods.
Biological inquiry on detected significant genes
The performed screens yield several interesting hits of
which most are novel to the corresponding pathogen
(Figure 5A, see Additional file 1: Figure S10 for cell
number hits). Many of the strongest hits, including
MTOR, TGFBR1/2 for negative hits and ILK for positive
hits, were shared between most of the studied patho-
gens. This was also illustrated by the sharedness scores
of detected hit genes. Many of the strongest shared hits
were related to SRC, MTOR, or CDK related pathways.
Although SRC and CDK4 were not part of the hit lists
(qpg < 0.4) for any of the pathogens, they exhibited con-
sistent semi-strong effect for most pathogens. A network
analysis of hit genes showed that several of the shared
hits can be described as “network hubs” that are in-
volved in many cellular processes and highly connected
to other genes (including MTOR and SRC) (Figure 5B)
[43]. MTOR is a mammalian target of rapamycin, serine/
threonine protein kinase that regulates cell growth, cell
proliferation, cell motility, cell survival, protein synthesis,
and transcription. The involvement of MTOR in Adeno-
virus, Poliovirus, Enterovirus71, Coxackievirus, Vaccinia
virus and other pathogens has already been established
[6,9,15]. Our data also reproduced the established role of
MTOR during S. typhimurium infections, since S. typhi-
murium depends on a reactivation of MTOR during its
course of infection in order to escape autophagy [38].
Interestingly, TGFBR1 and TGFBR2 came up both as
strong hits for many pathogens. TGFBR1 and TGFBR2
proteins must heterodimerize to form a functional TGF-
beta receptor at the plasma membrane. Their similar
strong infection reducing knock-down phenotypes, seen
in most independent pathogen screens, indicated the
validity of these hits and suggested a broad, yet poorly
understood, function of this membrane protein for various
pathogens. In particular, there are suggestions [44] that
the TGFB pathway might be important for B. abortus in-
fection since in chronic brucellosis patients there is in-
creased TGF beta production and this could aid infection
by depressing lymphocyte functions. In addition, our study
confirmed the role of DYRK family members (in particular
DYRK1A) as they have been identified to be general
regulators for several viruses in Snijder, Sacher et al. [9].
Despite the overall similarity of infection patterns be-
tween pathogens, most pathogens also contained hits thatwere specific for the pathogen (for example MET for L.
monocytogenes, NTPCR for B. henselae, and ETNK1 and
ULK1 for Rhinovirus). Some of the hit genes have previ-
ously been found to be effectors, for example MET for L.
monocytogenes. L. monocytogenes enters host cells by trig-
gering signaling cascades activated through interaction of
bacterial internalin A (InlA) or InlB with the adherens
junction protein E-cadherin or the hepatocyte growth
factor receptor MET [37] respectively. Since E-cadherin is
not expressed in HeLa cells, which were used for our
siRNA screens, the INLB / MET pathway is the only route
of entry in this cellular system. In fact, MET [45] was one
of the strongest hits for L. monocytogenes. The exact roles
of most hit genes of all pathogens are largely unknown,
but several hit genes create interesting hypotheses for
follow-up. For example, it was proposed based on micro-
RNA analysis of infected macrophages, that AMPK might
be a target gene that promotes intracellular survival during
B. abortus infection [46]. PIK3R3 (p55-gamma; Phos-
phatidylinositol 3-Kinase 55 KD a Regulatory Subunit
Gamma) a semi-strong hit for several pathogens in our
data was identified as a hit in an RNAi screen of drosoph-
ila S2 cells, in agreement with the importance of PI3K
during B. abortus infection [47]. PIK3CA probably plays a
role also in B. henselae infection through actin modula-
tion. PIK3CA levels influence RHOA and RAC1, which are
involved in actin dynamics [48]. Furthermore, PIK3CA is
involved in PIP3 production, which is a signaling molecule
and has recently been shown to be related to the forma-
tion of dynamic F-actin-related structures [49]. ULK1
(unc-51 like autophagy activating kinase 1) plays an im-
portant role in autophagy as well as Hepatitis C virus in-
fection. Therefore, ULK1 has a possible link to Rhinovirus
induced autophagy. COL4A3BP is possibly linked to
Rhinovirus entry through ceramide-enriched membrane
platforms [50] since COL4A3BP specifically phosphory-
lates the N-terminal region of the non-collagenous do-
main of the alpha 3 chain of type IV collagen, known as
the Goodpasture antigen, also involved in ceramide intra-
cellular transport (from ER to Golgi).
Conclusions
We produced a uniquely wide high-content siRNA data-
set, in terms of used siRNA libraries (11 single siRNAs
and one pool) and eight different pathogens. Our highly
unified protocols and common image analysis as well as
similar data analysis pipelines enabled a direct compari-
son between the phenotypic readouts of the different
pathogen screens. The unified structures of the datasets
also aided discovering shared mechanisms between the
studied pathogens.
Using our novel statistical approach PMM we detected
several interesting and new hits from our kinome-wide
pathogen screens. The hits will require further follow-up
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nisms of the genes. In addition, we discovered shared
effector genes between the studied pathogens including
MTOR, TGFBR1 and TGFBR2 that were strong hits for
almost all studied pathogens. In particular, the obtained
sharedness scores indicated whether a hit gene has a
very specific function for a single pathogen or a more
generic cellular function that is shared between many
pathogens and thus gave us the first indications of the
gene’s roles. Pharmaceutically oriented follow-up studies
could take advantage of this concept. For example, if we
were interested in general regulators we could focus on
genes with high sharedness scores. On the other hand,
regulators that have a very specific effect and a low
sharedness score could probably have fewer side effects.
We showed that the reliability of hit scoring in individ-
ual RNAi screens improved by using PMM that takes ad-
vantages of the parallelism in RNAi screening. PMM can,
in principle, be applied to any kind of parallel RNAi
screens almost independently of the underlying biology or
field of application as long as the readouts of the screens
are measured on the same scale. We can often obtain this
by applying Z-Scoring or similar normalization methods
to the well readouts. The difference to other approaches
aiming at the comparison of independent parallel RNAi
screens is that PMM takes simultaneously all screening
data into account. For example, for the comparison of in-
sect and human data in [51] the hit lists were derived by
separate statistics on each screen. By taking all data into
the analysis the statistical power can be increased. Based
on our results, we expect that the more similar the parallel
screens are in the sense of biological focus or protocols,
the more statistical power can be gained from the simul-
taneous analysis. Even a slight overlap between the under-
lying biological pathways of the parallel screens can
improve the hit detection in individual screens without
compromising the detection of unique hits for any individ-
ual screens. Provided that the large-scale RNAi screening
community reaches standardized data publication and
sharing standards through projects such as MIARE and
GenomeRNAi, the PMM approach could be expanded to
include the vast number of different RNAi screens per-
formed in different laboratories worldwide that used the
same siRNA libraries. In principle and as a vision, this
opens up great opportunities for simultaneous statistical
approaches such as PMM. Every new screen could poten-
tially gain statistical power by using the public resources.
In addition, PMM can potentially be used to gain power
for secondary validation screens. Such validation screens
are typically performed with several independent siRNAs
targeting the same gene under various conditions and
PMM would be directly applicable. A beneficial feature of
PMM is the possibility to assign weights to the siRNAs.
The weights can incorporate a-priori information aboutthe performance of individual siRNAs and their phenotyp-
ical readout. This concept of weighting can be expanded
over what we presented in this paper. In particular, statis-
tical and bioinformatics analyses on seed sequence induced
off-target effects could potentially be used as basis for
weights. Naturally any additional high-throughput data,
such as proteomics analyses on cells under siRNA pertur-
bations, or genomic analyses on specific cell lines, could be
used to assign realistic siRNA weights to improve hit
scoring.
We aimed to take a step forward in determining min-
imal requirements for image-based RNAi screening data
publication. All the raw images, library metadata, single
cell measurements, and well measurements are publicly
available through our openBIS based publication portal.
In addition, we provide easy-to-access data aggregates in
standardized tabular formats with all the necessary
metadata information. Our uniquely wide datasets pro-
vide a large resource for infection biologists, image
analysts, and statisticians for future research.Methods
Wet-lab protocols
Cell culturing conditions
HeLa CCL-2 (ATCC) cells were maintained at 37°C and
5% CO2 in Dulbecco Modified Eagle Medium (DMEM,
Invitrogen) supplemented with 10% inactivated FCS
(Invitrogen).siRNA reverse transfection
RNA interference directed against human kinases and
kinase-associated genes (826 genes in total) was achieved
using commercially available siRNA libraries. All experi-
ments were conducted in a 384-well plate format. In
addition to screening plates, control plates were included
in each screen. All plates contained general siRNA con-
trols for transfection efficiency and toxicity (e.g. Kif11),
as well as, control siRNAs for infection effects of each
pathogen assayed. However, for most of the pathogens
in this study, reliable and well established positive con-
trol siRNAs (reducing or enhancing infection levels)
were not available prior to screening. In addition, nega-
tive controls such as MOCK (no siRNA) and SCRAM-
BLED (non-targeting siRNA) were added to every plate.
In each experiment, 25 μl of RNAiMAX/DMEM (0.1 μl/
24.9 μl) mixture was added to each well of the screening
plates containing 1.6 pmol siRNA diluted in 5 μl RNase-
free ddH2O. Screening plates were thereafter incubated at
room temperature (RT) for 1 h. Following incubation, a
pathogen assay-specific number of HeLa CCL-2 cells (see
Additional file 1: Table S1) were added per well in a
volume of 50 μl DMEM/16% FCS, resulting in a final FCS
concentration of 10% (Adenovirus screens contained 6.7%
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72 h prior to infection.
Fixation and staining
After infection cells were fixed using paraformaldehyde
(PFA). Cells were stained for DNA, F-actin and infection
specific markers. Screening plates were sealed prior to
imaging.
Adenovirus-specific protocol
All liquid handling stages of infection, fixation, and
immunofluorescence staining were performed on the
automated pipetting system Well Mate (Thermo Scientific
Matrix) and washer Hydrospeed (Tecan). For infection
screens recombinant Ad2_ΔE3B-eGFP (short Adenovirus)
was utilized as described before [52,53]. Adenovirus was
added to cells at a multiplicity of infection (moi) of 0.1 in
10 μl of an infection media/FBS (DMEM supplemented
with L-glutamine, 10% FBS, 1% Pen/Strep, Invitrogen).
Screening plates were incubated at 37°C for 16 h, and cells
were fixed by adding 21 μl of 16% PFA directly to the cells
in culture media for 45 min at RT or long-term storage at
4°C. Cells were washed 2 times with PBS/25 mM NH4Cl,
permeabilized with 25 μl 0.1% Triton X-100 (Pharmacie-
biothek). After 2 washes with PBS the samples were incu-
bated at RT for 1 h with 25 μl staining solution (PBS)
containing DAPI (1 μg/ml, Sigma-Aldrich) and DY-647-
phalloidin (1 U/ml, Dyomics),washed 2 times with PBS
and stored until imaging in 50 μl PBS/NaN3.
Bartonella henselae -specific protocol
Bacterial strain SEB0109: Bartonella henselae ATCC49882T
ΔbepG containing plasmid pCD353 [54] for IPTG-
inducible expression of GFP. Culturing conditions: bac-
teria were grown on Columbia base agar (CBA) plates
supplemented with 5% defibrinated sheep blood (Oxoid)
and 50 μg/ml kanamycin. Bacteria were incubated at 35°C
in 5% CO2 for 72 h before re-streaking them on fresh
CBA and further growth for 48 h. Infection: siRNA-
transfected cells were washed once with M199 (Invitro-
gen)/10% FCS using a plate washer (ELx50-16, BioTek).
Cells were infected with B. henselae at an MOI of 400 in
50 μl of M199/10% FCS and 0.5 mM IPTG (Applichem)
and were incubated at 35°C in 5% CO2 for 30 h. Fixation
at RT: using a Multidrop 384 (Thermo Scientific) cells
were washed with 50 μl of PBS, fixed in 20 μl of 3.7% PFA
for 10 min, and washed once more with 50 μl of PBS.
Staining on a Biomek liquid handling platform: fixed cells
were washed twice with 25 μl of PBS and blocked in PBS/
0.2% BSA for 10 min. Extracellular bacteria were labeled
with a rabbit serum 2037 against B. henselae [23] and a
secondary antibody goat anti rabbit Alexa Fluor 647
(Jackson Immuno) in PBS/0.2% BSA. Antibodies were
incubated for 30 min each and both incubations werefollowed by two washings with 25 μl of PBS. Cells were
then permeabilized with 20 μl of 0.1% Triton X-100
(Sigma) for 10 min and afterwards washed twice with
25 μl of PBS, followed by the addition of 20 μl of staining
solution (PBS containing 1.5 U/ml DY-547-Phalloidin
(Dyomics) and 1 ug/ml DAPI (Roche)). After 30 min of in-
cubation in the staining solution, cells were washed twice
with 25 μl PBS, followed by a final addition of 50 μl of
PBS.
Brucella abortus -specific protocol
Brucella abortus 2308 pJC43 (aphT::GFP) [55] were grown
in tryptic soy broth (TSB) medium containing 50 μg/ml
kanamycin for 20 h at 37°C and shaking (100 rpm) to an
OD of 0.8-1.1. 50 μl of DMEM/10% containing bacteria
was added per well to obtain a final moi of 10000 using a
cell plate washer (ELx50-16, BioTek). Plates were then
centrifuged at 400 g for 20 min at 4°C to synchronize
bacterial entry. After 4 h incubation at 37°C and 5% CO2,
extracellular bacteria were killed by exchanging the infec-
tion medium by 50 μl medium supplemented with 10%
FCS and 100 μg/ml gentamicin (Sigma). After a total in-
fection time of 44 h cells were fixed with 3.7% PFA for
20 min at RT with the cell plate washer. Staining was
performed using a Biomek liquid handling platform. Cells
were washed twice with PBS and permeabilized with 0.1%
Triton X (Sigma) for 10 min. Then, cells were washed
twice with PBS, followed by addition of 20 μl of staining
solution which includes DAPI (1 μg/ml, Roche) and DY-
547-phalloidin (1.5 U/ml, Dyomics) in 0.5% BSA in PBS.
Cells were incubated with staining solution for 30 min at
RT, washed twice with PBS, followed by final addition of
50 μl PBS.
Listeria monocytogenes -specific protocol
After washing an overnight culture of L. monocytogenes
EGDe.PrfA*GFP three times with PBS, bacteria were di-
luted in DMEM supplemented with 1% FCS. Cells were
infected at a moi of 25 in 30 μl infection medium per
well. After centrifugation at 1000 rpm for 5 min and in-
cubation for 1 h at 37°C in 5% CO2 to allow the bacteria
to enter, extracellular bacteria were killed by exchanging
the infection medium by 30 μl DMEM supplemented
with 10% FCS and 40 μg/ml gentamicin (Gibco). Both
medium exchange steps were carried out with a plate
washer (ELx50-16, BioTek). After additional 4 h at 37°C
in a 5% CO2 atmosphere, cells were fixed for 15 min at
RT by adding 30 μl of 8% PFA in PBS to each well using
a multidrop 384 device (Thermo Electron Corporation).
PFA was removed by four washes with 500 μl PBS per
well using the Power Washer 384 (Tecan). Fixed cells
were stained for nuclei, actin and bacterially secreted InlC.
First, cells were incubated for 30 min with 10 μl/well of
primary staining solution (0.2% saponin, PBS) containing
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with 40 μl PBS per well cells were stained with 10 μl/well
of the secondary staining solution (0.2% saponin, PBS)
containing Alexa Fluor-546 coupled anti-rabbit antibody
(1:250, Invitrogen), DAPI (0.7 μg/ml, Roche), and DY-647-
Phalloidin (2 U/ml, Dyomics). After four washes with
40 μl PBS per well, the cells were kept in 40 μl PBS per
well. The staining procedure was carried out with a Tecan
freedom evo robot.
Rhinovirus-specific protocol
All liquid handling stages of infection, fixation, and
immunofluorescence staining were performed on the
automated pipetting system Well Mate (Thermo Scientific
Matrix) and washer Hydrospeed (Tecan). For infection
assays with human Rhinovirus serotype 1a (HRV1a) were
carried out as described, except that the anti-VP2 antibody
Mab 16/7 was used for staining of the infected cells as de-
scribed earlier [56-58]. Rhinovirus at a moi of 8 was added
to cells in 20 μl of an infection media/BSA (DMEM sup-
plemented with GlutaMAX, 30 mM MgCl2 and 0.2% BSA,
Invitrogen). Screening plates were incubated for 7 h at
37°C, and cells were fixed by adding 33 μl of 16% PFA
directly to the culture medium. Fixation was either for
30 min at RT or long term storage at 4°C. Cells were
washed twice with PBS/25 mM NH4Cl, permeabilized
with 50 μl 0.2% Triton X-100 (Sigma-Aldrich) followed by
3 PBS washes and blocking with PBS containing 1% BSA
(Fraction V, Sigma-Aldrich). Fixed and permeabilized cells
were incubated at RT for 1 h with diluted mabR16-7 anti-
body (0.45 μg/ml) in PBS/1% BSA. Cells were washed 3
times with PBS and incubated with 25 μl secondary stain-
ing solution (PBS/1% BSA) containing Alexa Fluor 488
secondary antibody (1 μg/ml, Invitrogen), DAPI (1 μg/ml,
Sigma-Aldrich), and DY-647-phalloidin (0.2 U/ml,
Dyomics). Cells were washed twice with PBS after 2 h of
incubation in secondary staining solution and stored in
50 μl PBS/NaN3.
Salmonella typhimurium -specific protocol
All liquid handing stages of infection, fixation, and im-
munofluorescence staining were performed on a liquid
handling robot (BioTek; EL406). For infection the S.
typhimurium strain S.TmSopE_pM975 was used. This strain
is a single effector strain, only expressing SopE out of
the main four SPI-1 encoded effectors (SipA, SopB,
SopE2 and SopE). Additionally this strain harbors a plas-
mid (pM975) that expresses GFP under the control of a
SPI2 (ssaG)-dependent promoter. The bacterial solution
was prepared by cultivating a 12 h culture in 0.3 M LB
medium containing 50 μg/ml streptomycin and 50 μg/
ml ampicillin. Afterwards a 4 h subculture (1:20 diluted
from the 12 h culture) was cultivated in 0.3 M LB
medium containing 50 μg/ml streptomycin, whichreached an OD600nm ≈ 1.0 after the respective 4 h of in-
cubation time. To perform the infection, 16 μl of diluted
S. typhimurium (moi = 80) were added to the HeLa cells.
After 20 min of incubation at 37°C and 5% CO2, the S.
typhimurium-containing media was replaced by 60 μl
DMEM/10% FCS containing 50 μg/μl streptomycin and
400 μg/μl gentamicin to kill all remaining extracellular
bacteria. After additional 3 h 40 min incubation at 37°C
and 5% CO2, cells were fixed by adding 35 μl 4% PFA, 4%
sucrose in PBS for 20 min at RT. The fixation solution
was removed by adding 60 μl PBS containing 400 μg/ml
gentamicin. Cells were permeabilized for 5 min with 40 μl
0.1% Triton X-100 (Sigma-Aldrich). Afterwards 24 μl of
staining solution containing DAPI (1:1000, Sigma-Aldrich)
and DY-547-phalloidin (1.2 U/ml, Dyomics) was added
(prepared in blocking buffer consisting of 4% BSA and 4%
Sucrose in PBS). After 1 h of incubation at RT, cells were
washed three times with PBS followed by the addition of
60 μl PBS containing 400 μg/ml gentamicin.
Shigella flexneri -specific protocol
S. flexneri M90T ΔvirG pCK100 (PuhpT::dsRed) were
harvested in exponential growth phase and coated with
0.005% poly-L-lysine (Sigma-Aldrich). Afterwards, bacteria
were washed with PBS and resuspended in assay medium
(DMEM, 2 mM L-Glutamine, 10 mM HEPES). 20 μl of
bacterial suspension was added to each well with a final
moi of 15. Plates were then centrifuged for 1 min at 37°C
and incubated at 37°C and 5% CO2. After 30 min of infec-
tion, 75 μl were aspirated from each well and monensin
(Sigma) and gentamicin (Gibco) were added to a final con-
centration of 66.7 μM and 66.7 μg/ml, respectively. After a
total infection time of 3.5 h, cells were fixed in 4% PFA for
10 min. Liquid handling was performed using the Multi-
drop 384 (Thermo Scientific) for dispension steps and a
plate washer (ELx50-16, BioTek) for aspiration steps. For
immunofluorescent staining, cells were washed with PBS
using the Power Washer 384 (Tecan). Subsequently, cells
were incubated with a mouse anti-human IL-8 antibody
(1:300, BD Biosciences) in staining solution (0.2% saponin
in PBS) for 2 h at RT. After washing the cells with PBS,
Hoechst (5 μg/ml, Invitrogen), DY-495-phalloidin (1.2
U/ml, Dyomics) and Alexa Fluor 647-coupled goat
anti-mouse IgG (1:400, Invitrogen) were added and in-
cubated for 1 h at RT. The staining procedure was per-
formed using the Biomek NXP Laboratory Automation
Workstation (Beckman Coulter).
Vaccinia virus-specific protocol
All liquid handing stages of infection, fixation, and im-
munofluorescence staining were performed on a liquid
handling robot (BioTek, EL406). For infection assays a
recombinant WR VACV, WR E EGFP/L mCherry, was
utilized. For infection, media was aspirated from the
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virus solution per well (moi = 0.125). Screening plates
were incubated for 1 h at 37°C to allow for infection,
after which virus-containing media was removed and
replaced with 40 μl DMEM/10% FCS. 8 h after infection
40 μl of DMEM/10%FCS containing 20 μM cytosine ara-
binoside (AraC) was added to all wells to prevent virus
DNA replication in secondary infected cells. 24 h after
infection cells were fixed by the addition of 20 μl 18%
PFA for 30 min followed by two PBS washes of 80 μl.
For immunofluorescence staining of EGFP, cells were in-
cubated for 2 h in 30 μl primary staining solution (0.5%
Triton X-100, 0.5% BSA, PBS) per well, containing anti-
GFP antibody (1:1000). Cells were washed twice in 80 μl
PBS, followed by the addition of 30 μl secondary staining
solution (0.5% BSA, PBS) containing Alexa Fluor 488
secondary antibody (1:1000), Hoechst (1:10000), and
DY-647-phalloidin (1:1200, Dyomics). Cells were washed
twice with 80 μl PBS after 1 h incubation in secondary
staining solution followed by the addition of 80 μl H2O.
Microscopy
Microscopy was performed with Molecular Devices Ima-
geXpress microscopes. We used the MetaXpress plate
acquisition wizard with no gain, 12 bit dynamic range, 9
sites per well in a 3×3 grid with no spacing and no overlap
and laser-based focusing. Channels were assay specific
(see Additional file 1: Table S2). Robotic plate handling
was used to load and unload plates (Thermo Scientific).
The objective was a 10X S Fluor with 0.45NA. The Site
Autofocus was set to “All Sites” and the initial well for
finding the sample was set to “First well acquired”. Z-
Offset for Focus was selected manually and “AutoExpose”
was used to get a good exposure time. Manual correction
of the exposure time was applied to ensure a wide
dynamic range with low overexposure, when necessary.
Statistical analyses
Image analysis and data normalization
Image analysis and data normalization was based on
modified CellProfiler [28] workflows. Please refer to
Additional file 1 for detailed description of computational
infrastructure, image analysis, and data normalization.
Parallel Mixed Model (PMM)
We denote the readout of siRNA s silencing gene g for a
pathogen g as ypgs. The linear mixed model of PMM is
defined as the following linear model
ypgs ¼ μp þ ag þ bpg þ εpgs;
age N 0; σ2a ; bpge N 0; σ2b ; εpgse N 0; σ2ε ;
where μp is the fixed effect for pathogen p (typically close
to 0 because of data Z-Scoring), ag is the gene effectoverall pathogens, bpg is the gene effect within a pathogen
and εpgs denotes the error term. The parameters are esti-
mated by maximizing the restricted maximum likelihood
using the Newton–Raphson algorithm [33]. We used the
implemented version in the “lmer” function from the
“lme4” R-package [34]. This implementation allows also
the use of weights, which are incorporated by a weighted
maximum likelihood formulation. The weights are con-
stant values where each constant corresponds to exactly
one data point. For our data, each weight is associated with
a single readout of an independent siRNA. The size of the
weight indicates the precision of the information contained
in the associated readout. The assumptions of the linear
mixed model are fulfilled (see Additional file 1: Figure
S11).
Local false discovery rate (q) estimation in PMM
The observed distribution of the estimated cpg is a mix-
ture of the null f0 and the non-null distribution f1. The
null distribution describes the distribution of all genes
that are no-hits. The non-null distribution corresponds
to the genes that are hits, having either a positive or
negative effect. The two distributions are assumed to dif-
fer only in the mean. The non-null distribution is shifted
by a factor ϴ away from zero. With this we define the
local false discovery rate as
f dr cð Þ¼PðNo Hit jcÞ¼π0f 0 cð Þ
f cð Þ
f 0 e N 0;σ2aþσ2b ;f 1 eN θ;σ2aþσ2b ;
f cð Þ¼π0f 0 cð Þþ π1f 1 cð Þ
where π0 = proportion of true hits and π1 = 1 − π0 [59].
The three quantities needed for the estimation of the
false discovery rate, are estimated separately by using
Maximum Likelihood, Poisson regression, and moment
estimation. The estimation procedure is implemented in
the function “locfdr” from the “locfdr” R-package [35].
Data resampling to show that parallel screens add power
We chose gene g and pathogen p for which we wanted to
show the increase in power by simultaneously using the
parallel screening structure. In our case, we repeated the
analysis for three different cases, consisting of a unique hit
(g: MET, p: L. monocytogenes), a shared hit (g: MTOR, p:
Vaccinia virus) and a non-hit (g: ALK, p: B. abortus). Each
time we resampled data for a fixed number of siRNAs
(ns = 2,…,11) and a fixed number of pathogens (np = 2,…,8)
from the full dataset. In detail, we chose randomly (np – 1)
pathogens and added additionally pathogen p. In the next
step, we sampled ns siRNA sets from the full available set
of siRNAs for every gene within all sampled pathogens.
We applied PMM on the sampled data and we reported
the rank of gene g within pathogen p. This was repeated
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step we calculated for each combination the mean and
variance of the rank for gene g within pathogen p. For the
resampling we omitted genes that have less than 6 siRNA
sets, in order to have a good resampling basis. Moreover,
we applied the same procedure for the case of np = 1 using
MTT.
Stability analysis
We resampled with replacement 1000 datasets from the
full data, taking for each gene the same number of siR-
NAs as in the full dataset. For each resampled dataset,
PMM, MTT and RSA were applied and the correspond-
ing ranking saved. For PMM the ranking was done ac-
cording to the absolute value of the estimated cpg effects,
for MTT we used the absolute values of the estimated
mean and for RSA the ranking based on the log(p)
values. We took absolute values to take into account
down and up hits simultaneously. From the 1000 rank-
ings we calculated the number of genes that appear with
high probability (prob > 0.9 and prob > 0.7) in the top k
(k = 1,…,50) of the ranking.
Hit overlaps examined by cross-validation
For the hit cross-validation analysis we only used data
coming from the siRNAs of all unpooled libraries (11 in
total). In each run, we ran PMM, MTT, and RSA on a
subset of the data consisting of 10 individual siRNAs
and used the remaining siRNA set as test set. For PMM
we ranked the results according to the absolute value of
the estimated cpg effects, for MTT we did ranking with
respect to the absolute values of the estimated mean, for
RSA we based the ranking based on the log(p) values
and for the test set we ordered the genes by the absolute
value of infection score. We counted the number of
genes that appeared in top k (k = 1,…,100) in both the
training and test sets. We determined the counts separ-
ately for each pathogen and averaged them in the end.
Data simulation and ROC-curves
We simulated data by generating 1000 normally distrib-
uted screens (mean = 0, std = 0.5) for eight pathogens,
taking 4 siRNAs each. Hits were incorporated in the
simulated screens by randomly selecting about 10% of
the genes (80 out of 826) and shifting them away from
zero. The shift was determined by a uniformly distrib-
uted random variable. We used the interval [0.2,0.3] as
parameter for the uniform distribution for “low shift”
and the interval [0.4,0.5] for “high shift”. We distin-
guished between three cases: In the first case the hits
were different for each pathogen (80 unique hits per
pathogen), in the second case all hits were shared be-
tween the pathogens (same 80 hits for all pathogens)
and in the third case we generated mixed hits (20 uniquehits, 20 hits shared between two pathogens, 20 hits
shared between four pathogens and 20 hits shared be-
tween all eight pathogens). PMM, MTT, and RSA were
applied to the simulated data and the ranking was saved.
For PMM the results were ranked according to the abso-
lute value of the estimated cpg effects, for MTT the rank-
ing was done with respect to the absolute values of the
estimated mean and for RSA the ranking based on the
log(p) values. For every ranking list we counted the num-
ber of true positives, true negatives, false positives and
false negatives in the top k (k = 1,…,826) and computed
the true positive rate (TPR = FP/(FP + TN)) and the false
positive rate (FPR = FP/(FP + TN)).
Influence of parallelism
For selected pathogen p we generated 1000 new datasets
by fixing the data of p and randomizing the data of the
other 7 pathogens. We applied PMM to each dataset
and saved the resulting ranking of p. In the next step we
aggregated the 1000 rankings by taking the average over
the cpg scores. We compared the averaged scores to the
gene rankings obtained by PMM performed using the
original dataset. We independently performed the study
for each pathogen.
Availability of supporting data
The data sets supporting the results of this article are
available on the InfectX openBIS data publication portal,
that is located at http://www.infectx.ch/dataaccess/. The
visitor username is “rdgr2014“ and the corresponding
password is “IXPubReview”. The R-package PMM and
related documentation is also available on this page.
Additional file
Additional file 1: Supplementary Information. The additional data file
1 contains supporting information und further analysis results.
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